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Tissue-resident memory CD8 + T (T RM ) cells are found at common sites of pathogen exposure, where they elicit rapid and robust protective immune responses 1,2 . However, the molecular signals that control T RM cell differentiation and homeostasis are not fully understood. Here we show that mouse T RM precursor cells represent a unique CD8 + T cell subset that is distinct from the precursors of circulating memory cell populations at the levels of gene expression and chromatin accessibility. Using computational and pooled in vivo RNA interference screens, we identify the transcription factor Runx3 as a key regulator of T RM cell differentiation and homeostasis. Runx3 was required to establish T RM cell populations in diverse tissue environments, and supported the expression of crucial tissue-residency genes while suppressing genes associated with tissue egress and recirculation. Furthermore, we show that human and mouse tumour-infiltrating lymphocytes share a core tissue-residency gene-expression signature with T RM cells that is associated with Runx3 activity. In a mouse model of adoptive T cell therapy for melanoma, Runx3-deficient CD8 + tumour-infiltrating lymphocytes failed to accumulate in tumours, resulting in greater rates of tumour growth and mortality. Conversely, overexpression of Runx3 enhanced tumour-specific CD8 + T cell abundance, delayed tumour growth, and prolonged survival. In addition to establishing Runx3 as a central regulator of T RM cell differentiation, these results provide insight into the signals that promote T cell residency in nonlymphoid sites, which could be used to enhance vaccine efficacy or adoptive cell therapy treatments that target cancer.
Long-lived memory T cells provide protection from reinfection and can serve as endogenous defenders against tumour growth 3 . Memory CD8 + T cell populations can be broadly segregated into circulating central memory (T CM ) and effector memory (T EM ) T cells as well as tissueresident memory (T RM ) T cells that primarily reside in non-lymphoid tissues without egress 4 . Circulating memory CD8 + T cells and T RM cells exhibit distinct gene-expression profiles [5] [6] [7] ; however, the early transcriptional identity of differentiating T RM cells and the signals controlling their fate are not yet fully appreciated. Here, we used an esta blished infection model with P14 T cell receptor transgenic CD8 + T cells responsive to the lymphocytic choriomeningitis virus (LCMV) glycoprotein 33-41 peptide ) presented by major histocompatibility complex (MHC) class I H-2D b . In this acute infection model, adoptively transferred P14 cells located in non-lymphoid tissues on day 7 of infection began to upregulate molecules characteristic of T RM cells 8 , including key tissue-retention molecules CD103 and CD69 (Extended Data Fig. 1a ). Gene expression analysis revealed that 90-96% of the genes upregulated in mature P14 T RM cells in the kidney parenchyma or intraepithelial lymphocyte (IEL) compartment of the small intestine were increased in T RM precursor cells relative to splenic effector cells on day 7 of infection ( Fig. 1a ). Furthermore, analysis of genes differentially expressed between splenic and non-lymphoid populations on day 7 of infection revealed two distinct gene expression programs that segregated circulating (peripheral blood lymphocytes, spleen, T CM and T EM ) from non-lymphoid (kidney and IELs) P14 cells, independent of the infection time point (Fig. 1b) . Lymph node or splenic KLRG1 lo CD127 hi memory precursor cells preferentially give rise to circulating memory populations, whereas shorter-lived KLRG1 hi CD127 lo terminal effector cells exhibit less memory potential 3 . Day 7 IEL P14 cells comprising the precursors of T RM cells were transcriptionally distinct from splenic memory precursor cells (Fig. 1c) . This is notable, as IEL T RM cells are predominantly KLRG1 lo (ref. 9) and preferentially differentiate from lymphoid-derived KLRG1 lo precursors seeding non-lymphoid tissues on days 4.5-7 of infection 10 (Extended Data Fig. 1a-c) , consistent with studies of skin T RM cells 5 . Thus, the T RM precursor cell populations in non-lymphoid tissues are transcriptionally distinct from circulating effector cells as well as memory precursor cells on day 7 of infection, and most of the T RM cell transcriptional program is already established at this time point, before contraction of the CD8 + T cell population.
As chromatin accessibility is a key determinant of cell identity and fate, we profiled non-lymphoid and splenic effector populations using an assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) on day 7 of infection. Uniquely accessible chromatin regions were identified in IEL P14 cells near genes characteristically expressed in mature T RM cells (for example, Cd69 and Nr4a1), whereas genes that promote T cell re-circulation (for example, Klf2 and S1pr1) exhibited loss of accessible regions (Extended Data Fig. 2a ). Principal component analysis (PCA) highlighted that, despite day 7 being an 'effector' time point, the global chromatin landscape markedly differs between effector CD8 + T cells located in the spleen, including memory precursor cells, and those located in non-lymphoid tissues (Fig. 1d ). The unique chromatin configuration of differentiating T RM cells is consistent with the notable transcriptional differences observed ( Fig. 1a-c) and foresha dows the distinct fates of antigen-specific cells in the spleen relative to non-lymphoid tissues. Thus, precursors of T RM cells in non-lymphoid sites are a unique and distinct CD8 + T cell subset relative to effector cells in the lymphoid compartment, including the memory precursor cell population.
Specification of CD8 + T cell fate during infection is dependent on the integrated activity of multiple transcription factors 3 ; regulators of T RM cell formation include Hobit 6 , Blimp1 6 , Nr4a1 11 , Eomes 12 and T-bet 12, 13 . To facilitate a broader understanding of the transcriptional network driving T RM cell differentiation, we used a combined screening approach, consisting of a computational strategy integrating ATACseq data, transcriptional profiling and personalized PageRank analysis to predict regulatory transcription factors, and a pooled in vivo RNA interference (RNAi) loss-of-function screen targeting putative T RM cell Letter reSeArCH regulators identified through the computational approach (Fig. 1e) . We recently demonstrated that analysis of accessible transcription factor-binding motifs and target gene expression yielded insight into factors with regulatory functions in the differentiation of circulating memory CD8 + T cells 14 . Using this approach and the personalized PageRank analysis 15 , we predicted several transcription factors with established regulatory roles in controlling T RM cell differentiation (such as Blimp1 6 , Nr4a1 11 , Eomes 12 and T-bet 12, 13 ) and many with no previously described role in T RM cells ( Fig. 1f, Supplementary Table 1 ). We evaluated both barrier (IEL) and non-barrier (kidney) T RM cells to reveal transcription factors important to T RM cell differentiation independent of the tissue. In addition, a key strength of this computational screen is that influential roles of differentially expressed transcription factors as well as those with homogenous expression can be anticipated (Extended Data Fig. 2b ). To establish functional relevance for predicted regulators of T RM cell formation identified Red denotes genes increased in T RM relative to T CM and T EM cells; blue denotes genes increased in T CM and T EM relative to T RM cells. Bottom, comparison of differentially expressed genes in mature T RM cells (from top panel) in cells from the spleen, IELs or kidney on day 7 of infection. b, Differentially expressed genes between splenic, IEL and kidney populations on day 7 of infection were compared among effector and memory CD8 + T cell subsets. Populations are ordered by hierarchical clustering with Pearson correlation. c, PCA of differentially expressed genes among day 7 subsets and naive P14 cells. MP, memory precursors; TE, terminal effectors. d, PCA of differential global chromatin accessibility of subsets on day 7 of infection identified by ATAC-seq analysis. e, Combinatorial screening approach. TF, transcription factors. f, Transcription factors with a PageRank score of ≥ 1.5-fold change for day 7 non-lymphoid cells compared to day 7 splenic cells are included in the heat map; proteins known to regulate T RM cell formation are in bold font. g, Enrichment of shRNAmir constructs in IEL T RM cells relative to splenic T CM cells from the RNAi screen, reported as the average Z-score from 3 independent screens, in which each independent screen was performed by pooling DNA from sorted P14 cells from n = 15, n = 18 and n = 18 mice. Each time point represents an individual experiment consisting of 2-3 biological replicates, in which cells from 2-10 mice were pooled for each replicate (a-d).
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through PageRank analysis, we used an RNAi screening strategy 16 to test hundreds of individual microRNA-based short hairpin RNA (shRNAmir) constructs in parallel for the ability to promote or repress T RM cell differentiation in vivo ( Fig. 1g , Supplementary Table 2) . Several transcription factors with established roles in regulating T RM cells were identified (such as Nr4a1 13 , Blimp1 6 , Klf2 17 and T-bet 12,13 ), as well as factors with previously unknown functions in controlling CD8 + T RM formation such as Nr4a3 and Runx3 (Fig. 1g ).
Runx3 is a well-established regulator of CD8 + T cell thymocyte development 18 , supports cytotoxic activity of mature CD8 + T cells 19, 20 , and controls CD4 + T cell localization within the intestinal epithelium 21 . Although little is known regarding a role for Runx3 in CD8 + T RM cells, both computational and functional screens identified Runx3 as a putative regulator of T RM cell fate specification ( Fig. 1f , g) despite relatively uniform Runx3 expression in circulating and resident CD8 + T cell subsets (Extended Data Figs 2b, 3a) . We validated a role for Runx3 through a 1:1 mixed transfer of P14 cells transduced with control (Cd19 shRNAmir) or Runx3 shRNAmir-encoding retroviruses into mice that were subsequently infected with LCMV ( Fig. 2a ). Runx3 shRNAmir suppressed Runx3 expression (Extended Data Fig. 3b ) and impaired the formation of IEL T RM cells relative to circulating cells ( Fig. 2a and Extended Data Fig. 3c, d) , consistent with the RNAi screen. Furthermore, Runx3 RNAi also impaired T RM cell differentiation in the context of a localized enteric infection with Listeria monocytogenes expressing GP 33-41 (LM-GP 33-41 ) ( Fig. 2b) .
Next, using a tamoxifen-inducible deletion approach, Runx3 fl/fl Ert2-Cre + P14 (Runx3 fl/fl ) or Runx3 +/+ Ert2-Cre + P14 (Runx3 +/+ ) cells were mixed 1:1 and transferred into host mice followed by LCMV or enteric LM-GP 33-41 infection (Fig. 2c ). Runx3-deficiency resulted in a 2-6fold loss of splenocytes and minimal loss of mesenteric lymph node cells by day 15/16 of infection. However, Runx3-deficiency resulted in a 50-150-fold loss of CD69 + CD103 + T RM cells in both infection settings ( Fig. 2c and Extended Data Fig. 3e ). Moreover, delaying tamoxifen treatment to days 6-8 or 16-20 of infection further emphasized a distinct dependence of T RM cell differentiation on Runx3 (Fig. 2d ) as well as a crucial role for Runx3 in maintaining T RM cell homeostasis ( Fig. 2e , Extended Data Fig. 3f ). Furthermore, Runx3 was necessary for optimal T RM cell differentiation of H-2D b GP 33-41 tetramer + cells (Extended Data Fig. 4a-d ). Taken together, these data demonstrate that Runx3 is crucial for T RM cell differentiation and maintenance. 
Runx3 deletion also resulted in a loss of T RM cells in non-barrier tissues (salivary gland and kidney; Extended Data Fig. 5a , b), and optimal T RM cell differentiation in the skin and lung parenchyma required Runx3 (Extended Data Fig. 5c -h). Thus, the loss of T RM cells in a range of non-lymphoid tissues indicated that Runx3 drives the formation of T RM cells independently of the tissue site. Furthermore, Runx3 was required for maximal expression of granzyme B in T RM cells, although cytokine production was unchanged (Extended Data Fig. 6a, b ). Runx3-deficiency resulted in a greater frequency of annexin V + cells (Extended Data Fig. 6c, d ), most prominently in the CD69 + CD103 + T RM population; thus, the marked loss of T RM cells was at least in part due to a greater rate of apoptosis, as proliferation and trafficking were not affected (Extended Data Fig. 6e , f).
We next assessed whether enhanced expression of Runx3 could augment T RM cell differentiation. Overexpression of Runx3 accelerated IEL P14 CD69 + CD103 + T RM cell differentiation on day 8 of infection, but did not affect migration to the small intestine ( Fig. 3a ). Evidence of enhanced T RM cell differentiation was further confirmed by the greater abundance of IEL T RM cells on day 12/13 of infection and enhanced CD103 expression, consistent with a reported role for Runx3 in regulating CD103 expression 21, 22 (Fig. 3b ). Furthermore, overexpression of Runx3 also boosted T RM cell differentiation in the lung parenchyma (Extended Data Fig. 7a-d) .
Given that manipulation of Runx3 affected T RM cell formation in diverse tissue microenvironments, we constructed a core T RM cell transcriptional signature by computational integration of CD8 + T RM gene-expression datasets from small intestine IELs, kidney, lung 5 , skin 5 and brain 7 , to evaluate the hypothesis that Runx3 is a universal regulator of T RM cell specification ( Fig. 3c , Supplementary Table 3) . Notably, we found that most of the core tissue-residency signature genes were upregulated in Runx3-overexpressing cells and downregulated in Runx3-deficient cells. Conversely, the core signature of circulating memory cells was enriched in Runx3-deficient cells and depleted from Runx3-overexpressing cells ( Fig. 3c ). Therefore, Runx3 promoted the expression of tissue-residency signature genes and repressed genes characteristic of circulating cells. This conclusion was further corro borated by chromatin-immunoprecipitation followed by deep sequencing (ChIP-seq) analysis 23 , indicating that Runx3 binding was enriched in both core tissue-residency and circulating genes relative to background sites (Extended Data Fig. 8a ).
Through evaluation of accessible Runx3-binding motifs from ATAC-seq analysis, we generated a regulatory Runx3-binding network (Extended Data Fig. 8b ) and found that Runx3 putatively regulates a distinct network of genes in differentiating IEL-T RM precursor cells relative to splenic effector cells, including selective enrichment of genes linked to cell adhesion and regulation of transcription factor activity. In connection, Runx3 has been shown to cooperate with the transcription factor T-bet in many contexts 19, 24 , yet T-bet is a potent suppressor of early T RM cell differentiation 12, 13 . ChIP-seq data 23 indicated that Runx3 directly binds to multiple sites of the Tbx21 locus (encoding T-bet; Extended Data Fig. 8c ), and Runx3-deficient CD8 + T cells exhibited increased T-bet levels (Extended Data Fig. 8d ). Tbx21 RNAi in Runx3-deficient cells enhanced T RM cell numbers in the IEL compartment and restored CD103 and CD69 expression (Extended Data Fig. 8e , f), but did not fully rescue T RM cell differentiation. These findings are consistent with Runx3 regulating multiple targets that Letter reSeArCH influence T RM cell formation ( Fig. 3c ), including suppression of canoni cal genes associated with tissue egress (Extended Data Fig. 8g , h). It has been noted that CD8 + tumour-infiltrating lymphocytes (TILs) can exhibit characteristics of T RM cells, and a positive prognosis has been correlated with TILs that present qualities of T RM cells 25, 26 . As Runx3 regulates core features of tissue residency ( Fig. 3c ), we assessed the transcriptional similarities of TILs and T RM cells and evaluated a role for Runx3 in controlling TIL accumulation. TILs isolated from mouse melanoma 27 or mammary tumours 27 shared approximately 70% of the core tissue-residency gene-expression program relative to splenic CD8 + T cells (Fig. 4a ), and this relationship was further highlighted through PCA (Fig. 4b ). Utilizing an adoptive therapy model, Runx3-RNAi or Runx3-overexpressing P14 cells were mixed with control P14 cells at a 1:1 ratio and transferred into mice with established melanoma tumours expressing GP 33-41 (Extended Data Fig. 9a ). Runx3deficiency impaired TIL accumulation ( Fig. 4c, d ) without affecting migration to the tumour (Extended Data Fig. 9b ). Alternatively, Runx3overexpression enhanced TIL abundance ( Fig. 4c, d ), expression of granzyme B (Extended Data Fig. 9c ) and certain core tissue-residency genes while further suppressing core circulating genes (Fig. 4e ). In clinical settings, TIL density strongly correlates with positive outcomes 28 , and we observed Runx3-deficient P14 cells were impaired in their ability to control tumour growth, resulting in greater mortality ( Fig. 4f ). Conversely, Runx3-overexpressing cells delayed tumour growth and prolonged survival ( Fig. 4g ). Notably, human CD8 + TILs also exhibited enrichment of the core tissue-residency signature relative to circulating CD8 + T cells 25 (Extended Data Fig. 9d ), and analysis of single-cell RNA sequencing (RNA-seq) data from mouse 29 and human melanoma TILs 30 indicated that activated CD44 + CD8 + T cells expressing Runx3 exhibited enrichment of the tissue-residency gene-expression signature relative to CD44 + CD8 + TILs with low Runx3 expression levels (Fig. 4h ). These data indicate that in both human and mouse TILs, tissue-residency features are driven by Runx3. In connection, it was recently demonstrated that human lung cancer TILs enriched with certain qualities of T RM cells also correlated with TIL abundance and a positive prognosis 26 . Thus, the manipulation of transcription factors that promote tissue residency may yield more effective TILs and anti-viral memory T cells by supplementing CD8 + T cells with a gene-expression program that better supports features important to both T RM cells and TILs such as in situ survival, tissue retention, and repression of egress, ultimately fostering accumulation of protective T cells in tissues.
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Mice. Mice were maintained in specific-pathogen-free conditions in accordance with the Institutional Animal Care and Use Committees (IACUC) of the University of California, San Diego (UCSD) and The Scripps Research Institute, Jupiter, Florida (TSRI-FL). All mice were of a C57BL6/J background and bred at UCSD and TSRI-FL or purchased from the Jackson Laboratory, including: wild-type or P14 mice with distinct expression of the congenic molecules CD45.1, CD45.2, Thy1.1 and Thy1.2 as well as control Thy1.1 + Thy1.2 + Runx3 +/+ Ert2-Cre + YFP P14 mice and Runx3 inducible deletion Thy1.1 + Runx3 fl/fl Ert2-Cre + YFP P14 mice. Runx3 +/+ dLck-Cre + YFP and Runx3 fl/fl dLck-Cre + YFP mice were used for studying polyclonal CD8 + T cell responses. Male and female mice were used for experiments, and were age and sex matched, between 1.5 and 4 months old, and randomly assigned to experimental groups. The Rosa26 stop-flox enhanced yellow fluorescent protein (eYFP) reporter mice were used for all Runx3-deletion experiments. Cre-mediated deletion disrupts the Runx3 DNA-binding domain in exon 4, which exists in transcripts originating from both the distal and proximal promoter. Thus, both long and short Runx3 forms are inactivated in these alleles. Naive T cell transfers, infection and treatments. Naive P14 CD8 + T cells were transferred intravenously into congenically distinct sex-matched recipient mice, or female P14 cells were transferred into male mice. For all microarray, RNAseq or ATAC-seq experiments, a total of 1 × 10 5 P14 cells were transferred. For co-transfer experiments, naive Thy1.1 + Thy1.2 + Runx3 +/+ Ert2-Cre YFP + P14 cells and naive Thy1.1 + Runx3 fl/fl Ert2-Cre YFP + P14 cells were mixed 1:1 and a total of 3 × 10 4 P14 cells were transferred into Thy1.2 + recipient mice. Recipient mice were subsequently infected intraperitoneally with 2 × 10 5 plaque-forming units (PFU) of the Armstrong strain of LCMV or 10 10 colony-forming units (CFU) of L. monocytogenes expressing GP 33-41 via oral gavage 9 one day after cell transfer. For induced Runx3 deletion, recipient mice were intraperitoneally treated with 1 mg of tamoxifen diluted in sunflower oil on days 0-4, 2-5 or 6-8 of infection. For late deletion of Runx3 (days 16-20), recipient mice were treated with 2 mg of tamoxifen via oral gavage.
For T RM precursor experiments, 1 × 10 5 P14 cells were transferred, recipient mice were infected with LCMV the next day, and KLRG1 lo or KLRG1 hi P14 cells from spleens and lymph nodes were sorted on day 5 of infection. Sorted cells (1 × 10 5 ) were transferred into recipient mice infected 4 days previously with LCMV. The number of CD62L + T CM , CD62L − T EM , or IEL T RM cells were evaluated on days 20-25 of infection using flow cytometry.
To distinguish vascular-associated CD8 + T cells in non-lymphoid tissues, 3 μ g of CD8α (53-6.7) conjugated to allophycocyanin (APC) eFlour780 was injected intravenously into mice four minutes before euthanization and organ excision. CD8α neg cells were considered to be localized within non-lymphoid tissues. Preparation of cell suspensions. Isolation of CD8 + T cells was performed similarly as described 31 . For isolation of CD8 + T cells from the small intestine IEL compartment, Peyer's patches were removed and the intestine was cut longitudinally and subsequently cut laterally into 0.5-1 cm 2 pieces that were then incubated with 0.154 mg ml −1 dithioerythritol (DTE) in 10% HBSS/HEPES bicarbonate for 30 min at 37 °C while stirring. Kidneys, salivary glands, and lungs were cut into pieces and digested for 30 min with 100 U ml −1 type I collagenase (Worthington) in RPMI 1640, 5% FBS, 2 mM MgCl 2 , 2 mM CaCl 2 at 37 °C while shaking. Skin was processed similarly as previously described 32 , in which a 2 cm 2 area of the right flank was excised, pre-digested for 30 min at 37 °C and then enzymatically digested with 0.7 mg ml −1 collagenase D. After enzymatic incubations (skin, lungs, kidneys and salivary glands), tissues were further dissociated over a 70-μ m nylon cell strainer (Falcon). For isolation of lymphocytes, single-cell suspensions were then separated using a 44/67% Percoll density gradient. Spleens and lymph nodes were processed with the frosted ends of microscope slides. Red blood cells were lysed with ACK buffer (140 mM NH 4 Cl and 17 mM Tris-base, pH 7.4). Antibodies, intracellular staining, flow cytometry and cell sorting. The following antibodies were obtained from eBioscience: CD8α (53-6.7), CD8β (eBio H35-17.2), CD62L (MEL-14), CD127 (A7R34), KLRG1 (2F1), CD103 (2E7), CD69 (H1.2F3), CD45.1 (A20-1.7), CD45.2 (104), Thy1.1 (OX-7, HIS51), Thy1.2 (53-2.1), CCR9 (Ebio CW-1.2), CXCR3 (CXCR3-173), CD49d (R1-2), TNF (MP6-XT22), GzB (GB11), PD-1 (J43), Tim3 (RMT3-23), Lag3 (eBioC9B7N), KI-67 (SolA15), and IFNγ (XMG1.2) or from BioLegend: CD62L (MEL-14), CD103 (2E7), CD69 (H1.2F3), CD45.1 (A20-1.7), Thy1.1 (OX-7), Thy1.2 (30-H12), and T-bet (4B10). For analysis of apoptosis, the Annexin V Apoptosis Detection Kit was used per manufacturer instructions (eBioscience); propidium-iodidenegative cells were analysed for annexin V staining. The H-2D b GP 33-41 tetramer was obtained from the NIH Tetramer Core. For intracellular staining of cytokines or transcription factors while preserving ametrine or YFP reporter expression in transduced or Cre-YFP + populations, cells were fixed and permeabilized through a 10 min incubation with BD cytofix/cytoperm (BD Biosciences). Intracellular staining was subsequently performed using the Permeabilization Buffer of the Foxp3-Transcription Factor Staining Buffer Set (eBioscience). To assess cytokine production, CD8 + T cells were re-stimulated with the GP 33-41 peptide in the presence of Protein Transport Inhibitor Cocktail (eBioscience). For flow cytometry analysis, all events were acquired on a BD LSRFortessa X-20 or a BD LSRFortessa. Cell sorting was performed on BD FACSAria or BD FACSAria Fusion instruments. RNAi screening approach. We have described this screening approach in detail previously 16 . The targeted shRNAmir library was generated on the basis of key genes identified from the computational screening approach as well as genes with known roles in regulating T RM cells from literature. The library was produced by cloning shERWOOD-designed shRNAmir sequences 33 , after PCR of synthetic 97-mer oligonucleotides, into our pLMPd-Amt vector 16 . Purified DNA from sequence-verified clones was used to package retroviral particles in PLAT-E cells. The PLAT-E cell line was obtained from Cell Biolabs and were not authenticated or tested for mycoplasma contamination before use. For transfections, PLAT-E cells were seeded in the middle 60 wells of a 96-well flat-bottom plate at a density of 4 × 10 4 -6 × 10 4 cells per well one day before transfection. Next, each well was individually transfected with 0.2 μ g of DNA from each pLMPd-Amt clone and 0.2 μ g of pCL-Eco using TransIT-LT1 (Mirus). Retroviral supernatant was collected 36, 48 and 60 h after transfection, and retroviral supernatant from each well was used to individually transduce in vitro activated P14 cells in 96-well round-bottom plates.
For CD8 + T cell activation in vitro, naive CD8 + T cells from spleen and lymph nodes were negatively enriched and 2 × 10 5 P14 cells were plated in the middle 60 wells of 96-well round-bottom plates pre-coated with 100 μ g ml −1 goat anti-hamster IgG (H+ L, Thermo Fisher Scientific) and 1 μ g ml −1 anti-CD3 (145-2C11) and 1 μ g ml −1 anti-CD28 (37.51) (both from eBioscience). Culture medium was removed 18 h after activation, and replaced with retroviral supernatant supplemented with 50 μ M BME and 8 μ g ml −1 polybrene (Millipore) followed by spinfection (60 min centrifu gation at 805g, 37 °C). Two hours after the spinfection, the P14 cells were washed three times with cold PBS and 90% of each well of cells (individually transduced with distinct retroviral constructs) was collected, pooled and 5 × 10 5 pooled P14 cells were transferred into recipient mice, which were then infected 1 h later with 1.5 × 10 5 PFU of LCMV clone 13 intraperitoneally, resulting in an acute infection 16 . The remaining cells in vitro were cultured for an additional 24 h and either pooled for 'input' sequencing (6 × 10 5 P14 cells) or were used to test transduction efficiency of each construct using flow cytometry to detect the percentage of ametrine + cells in each well.
Twelve days after infection, spleens and small intestines were collected from 15-18 mice and splenocytes and IEL P14 cells were processed as described above. Before sorting, all IEL or splenic samples were pooled. CD62L + P14 cells (T CM ) from the spleen as well as P14 cells from the IEL were sorted (2 × 10 5 -6 × 10 5 cells total). Genomic DNA was then collected from sorted cells using the FlexiGene kit (Qiagen). The integrated proviral passenger strand shRNAmir sequences in each cell subset were amplified from 20-100 ng total genomic DNA per reaction, with 23-28 cycles of PCR using Ion Proton-compatible barcoded primers that anneal to the common 5′ mir30 and shRNAmir loop sequences. Between two and three replicate reactions were performed for each genomic DNA sample and the replicates were pooled after amplification. The pooled reactions were purified using AMPure XP beads, the amplicons in each sample were quantified using a Bioanalyzer, and then pooled in a 1:1 molar ratio for sequencing. In each replicate of the screen, a minimum of 2.5 million reads per sample were generated and retained, after filtering low-quality reads. Reads assigned to each barcode were aligned to a reference database of all shRNAmirs in the library using BLAST and a custom script to count the top alignment of each read and summarize the number of reads aligned to each shRNAmir.
For analysis of shRNAmir representation in T CM cells relative to IEL T RM , the total number of reads in each of the samples was normalized, and the number of reads for each shRNAmir was scaled proportionally. Subsequently, the normalized number of reads in the IEL T RM cells for a given shRNAmir was divided by the normalized number of reads for the same shRNAmir in the T CM sample and then log 2 transformed. The mean and s.d. of the ratios of each of the 25 negative-control shRNAmir constructs (targeting Cd19, Cd4, Cd14, Ms4a1, Cd22, Hes1, Klf12, Mafb, Plagl1, Pou2af1 and Smarca1) were used to calculate the Z-score for each shRNAmir construct. The screen was repeated three times and the Z-score of each construct from each individual screen was averaged and plotted ( Fig. 1g Supplementary Table 2 ). Certain constructs were added after the first screen or were not detectable in one of the screens, but all constructs were successfully screened 2-3 times except for 13 constructs, which are marked by an asterisk in Supplementary Table 2 . Eighty-four per cent (21 out of 25) of all negative control shRNAmir constructs had an average Z-score between − 0.9 and 0.9. CD8 + T cell transduction, cell transfer and infection for individual analysis of retroviral constructs. Activation, transfections and transductions were carried out as described for the RNAi screening approach except in some experiments 2 × 10 6 P14 cells were activated per well in 6-well plates. Congenically distinct P14 cells transduced with the Runx3.2 shRNAmir or Cd19.1 shRNAmir (control) retroviruses were mixed 1:1 within 24 h of transduction and a total of 1 × 10 5 -5 × 10 5 P14 cells were transferred intravenously into recipient mice. One hour after adoptive transfer, recipient mice were infected intraperitoneally or intratracheally with 2 × 10 5 PFU LCMV Armstrong or intradermally with 2 × 10 4 PFU clone 13. In similar experiments, P14 cells were transduced with MigR1-based retroviruses 34 that were empty (GFP-RV) or that contained Runx3 cDNA (Runx3-RV), mixed 1:1 and transferred to recipient mice for subsequent infections. For T-bet rescue experiments, Thy1.2 + Runx3 +/+ Ert2-Cre YFP + P14 cells were transduced with Cd19.1 shRNAmir and Thy1.1 + Runx3 fl/fl Ert2-Cre YFP + P14 cells were transduced with Tbx21.3 shRNAmir-encoding retroviruses, mixed 1:1 and transferred into recipient mice, which were infected 1 h later with LCMV Armstrong intraperitoneally and treated with 1 mg tamoxifen intraperitoneally for five consecutive days starting with the day of infection. Adoptive therapy tumour model. For adoptive therapy experiments, 5 × 10 5 B16-GP 33 cells, which were treated for mycoplasma and authenticated in in vitro killing assays, were transplanted subcutaneously into the right flank of wild-type mice. After tumours became palpable, 7-8 days after transplantation, in vitro expanded P14 cells were transferred intravenously. For comparison of TIL accumulation in a mixed transfer setting, naive P14 cells were activated, transduced and expanded with 100 U ml −1 of IL-2 for 2-3 days; cells transduced with control constructs (Cd19.1 shRNAmir or GFP-RV) or experimental constructs (Runx3.2 shRNAmir or Runx3-RV) were mixed 1:1 and 0.5 × 10 6 -1 × 10 6 P14 cells were transferred intravenously. For efficacy studies, transduced cells were expanded for 5-6 days; transduced cells were then sorted (or not sorted with a Runx3-RV and GFP-RV transduction efficiency > 83%), and 1 × 10 6 -2.5 × 10 6 cells were transferred intravenously into mice with established B16-GP 33 tumours. Tumours were monitored daily and mice with ulcerated tumours or tumours exceeding 1,500 mm 3 were euthanized, in accordance with UCSD IACUC. Quantitative PCR, microarray, RNA-seq and ATAC-seq analysis. For validation of the Runx3-RV overexpression construct and Runx3.2 shRNAmir construct, enriched CD8 + T cells were activated, transduced, and expanded for 4-6 days in 100 U ml −1 IL-2. Cells were sorted on ametrine (Runx3 shRNAmir or control shR-NAmir) or GFP (Runx3-RV or GFP-RV) directly into TRIzol (Life Technologies), and RNA was extracted per manufacturer's specifications. Next, cDNA was synthesized using Superscript II (Life Technologies) and quantitative PCR (qPCR) was performed using the Stratagene Brilliant II Syber Green master mix (Agilent Technologies). Runx3 expression levels were normalized to the housekeeping gene Hprt. We have previously validated the Tbx21.3 shRNAmir 16 . The following primers were used for qPCR: Runx3 forward, 5′-CAGGTTCAACGACCTTCGATT-3′, Runx3 reverse, 5′-GTGGTAGGTAGCCACTTGGG-3′; Hprt forward, 5′-GGCCAGACTTTGTTGGATTT-3′, Hprt reverse, 5′-CAACTTGCGCT CATCTTAGG-3′ .
On day 7 of infection, tissues from 2-3 mice were pooled and 2 × 10 4 -3 × 10 4 P14 cells from the IELs, kidney, spleen or blood were sorted into TRIzol. On day 35 of infection, tissues from 5-10 mice were pooled and 1 × 10 4 -2 × 10 4 CD62L + T CM , CD62L − T EM , kidney T RM , and IEL T RM P14 cells were sorted into TRIzol. As described previously, RNA was amplified and labelled with biotin and hybridized to Affymetrix Mouse Gene ST 1.0 micrroarrays 35 . Analyses were performed using GenePattern Multiplot Studio. Differentially expressed genes in IEL T RM compared to T CM and T EM cells as well as kidney T RM compared to T CM and T EM cells were identified with a fold change > 1.5 and an expression value > 120 (Fig. 1a) . Genes with > 1.5 fold change and > 120 expression value between day 7 spleen, day 7 IELs, and day 7 kidney samples were identified (1,838 probes) and evaluated in day 7 and day 35 subsets, which were ordered with Pearson correlation using the HierarchicalClustering module of GenePattern (Fig. 1b) ; data were row centred, row normalized, and visualized with the HierarchicalClusteringViewer module in GenePattern.
The core tissue-residency cells and circulating signatures were generated by integrating differential expression (> 1.5 fold change) data comparing T RM cells from the following tissues to circulating splenic memory cells (or splenic T CM if both T CM and T EM datasets were available): day 35 IELs (LCMV), day 35 kidney parenchyma (LCMV), day 30 skin CD103 + CD8 + (herpes simplex virus) 5 , day 30 lung CD103 + CD8 + (influenza virus) 5 , and day 20 CD103 + brain (vesicular stomatitis virus) 7 ; overlapping genes upregulated in all T RM cell populations comprised the core tissue-residency signature (121 genes) and genes downregulated in all populations comprised the circulating signature (93 genes). The mouse TIL microarray datasets were generated previously 27 .
For RNA-seq analysis of day 7 IEL, day 7 memory precursors, and day 7 terminal effectors, the populations were sorted on day 7 of LCMV Armstrong infection as well as naive P14 cells; spleens or IEL samples from 2-3 mice were pooled and 5 × 10 3 cells were sorted. For RNA-seq analysis of TIL, congenically distinct P14 cells were transduced with Runx3-RV or GFP-RV, mixed 1:1 and 1 × 10 6 cells were transferred to mice with day 7 established melanoma B16-GP 33 tumours. Eight days later, 1 × 10 3 transduced TILs or splenocytes were sorted from four mice for each replicate. For library preparation, isolation of polyA + RNA was performed as detailed online (http://www.immgen.com/Protocols/11cells.pdf). For RNA-seq analyses of Runx3-manipulated cells, CD8 + T cells from naive Runx3 +/+ YFP + (wild type) and Runx3 fl/fl YFP + (Runx3 fl/fl ) mice were enriched by negative isolation and transduced (as detailed above) with a Cre cDNA-expressing retrovirus (Cre-RV). Runx3-overexpressing cells were generated similarly by transducing Runx3 +/+ YFP + CD8 T cells with a Runx3 cDNA-expressing retrovirus (Runx3-RV). Forty-eight hours after T cell receptor activation, the CD8 + T cells were resuspended and re-cultured in fresh medium supplemented with 100 U ml −1 rhIL-2; 24 h later, YFP + (wild type or Runx3 fl/fl ) or GFP + (Runx3-RV) were FACSpurified and then recultured in 100 U ml −1 IL-2. The cells were expanded until day 6 by reculturing at 5 × 10 5 cells per millilitre every 24 h in fresh 100 U ml −1 IL-2 medium. On day 6 after activation, cells were collected and total RNA was extracted in TRIzol. Purified RNA was depleted of ribosomal RNA and strandspecific paired-end libraries were prepared and sequenced using an Illumina Nextseq 500. Samples were generated from two biological replicates, and approximately 20 million paired-reads were generated per sample. Reads were mapped using Tophat 36 and aligned reads in transcripts were counted with HTseq 37 . GSEA was performed by using the GSEA module in GenePattern, and the normalized enrichment scores and false-discovery rate q values were determined by using the permutation test.
ATAC-seq was performed as described in detail previously 24 . Sorted cells (2.5 × 10 4 ) were resuspended in 25 μ l of lysis buffer and spun down 600g for 30 min at 4 °C. The nuclear pellet was resuspended in 25 μ l of Tn5 transposase reaction mixture (Nextera DNA Sample Prep Kit, Illumina) and incubated for 30 min at 37 °C. Transposase-associated DNA was subsequently purified (Zymo DNA clean-up kit). For library amplification, DNA was amplified using indexing primer from Nextera kit and NEBNext High-Fidelity 2× PCR master mix. Then, the amplified DNA was size-selected to fragments less than 800 bp using SPRI beads. The library was sequenced using Hiseq 2500 for singleend 50-bp sequencing to yield at least 10 million reads. We used bowtie to map raw reads to the Mus musculus genome (mm10) with following parameters: '-best -m 1' . We called peaks for each individual replicate as well as the pooled data from the two replicates using MACS2 with a relaxed threshold (P = 0.01).
For the single-cell RNA-seq analysis of human 30 and mouse melanoma TILs 29 , the pre-processed single-cell TIL gene expression data were downloaded from GEO database with accessions GSE72056 or GSE86042, respectively. Activated CD8 + TILs (CD8α expression > 5 and CD44 expression > 2) were used and classified into Runx3 hi TILs, which express relatively high levels of Runx3 (Runx3 expression > 3) and Runx3 lo TILs with no Runx3 expression (Runx3 expression = 0). For the human TILs, melanoma #75 was used. GSEA was performed to evaluate enrichment of the core tissue-residency gene expression signature in Runx3 hi TILs relative to Runx3 lo TILs. Computational screen: transcription factor regulatory networks and personalized PageRank analysis. Transcription factor regulatory networks and PageRank analysis were performed as described previously 24 except that gene expression and ATAC-seq data from day 7 IEL, kidney and spleen samples were used. To construct the transcription factor regulatory network, transcription factor-binding motifs were first scanned on ATAC-seq peaks using an algorithm described previously 14 and a P-value cut-off of 1 × 10 −5 . Then, we connected a transcription factor to a gene if the factor had any predicted binding motif in the ATAC-seq peak of the nearest gene. We assembled all the interactions between transcription factors and genes into a regulatory network. To identify important transcription factor regulators for T RM cell differentiation, we performed personalized PageRank analysis in the transcription factor regulatory network constructed above using the pipeline described previously 14 . The importance of a transcription factor is based on the quantity and quality of its regulated gene targets. A factor would receive a higher PageRank score if it regulates more important genes, where the importance is evaluated by differential expression from microarray or RNA-seq analyses. Extended Data Fig. 2b and Supplementary Table 1 indicate the PageRank score and expression value of all transcription factors expressed (> 120 expression value) in the spleen, kidney or IEL cells. Statistical analysis. Student's t-test (two-tailed) was used for comparisons between two groups. A log-rank (Mantel-Cox) test was used to compare survival curves. All microarray, RNA-seq, and ATAC-seq samples were performed independently in Letter reSeArCH 2-3 replicates. All statistical tests were performed with GraphPad Prism software, and P < 0.05 was considered statistically significant. No statistical methods were used to predetermine sample size. Investigators were not blinded to allocation during experiments and outcome assessment. Data availability. RNA-seq, microarray, and ATAC-seq data are available in the Gene Expression Omnibus (GEO) database under the SuperSeries reference code GSE107395. Source Data are provided in the online version of the manuscript. All other data are available from the corresponding author(s) upon reasonable request. , d, e, g, h) . Corresponding author(s): Goldrath, A.G.
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Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity. Figure 4 d,e we also expected to see 50-75% difference in Runx3 shRNA TIL compared with control shRNA TIL or Runx3-RV compared to GFP-RV TIL; therefore, a sample size of n=3-7 was chosen to allow determination of at least a 50% reduction in TIL accumulation (t-test, α set at 0.05). For Figure 4 g,h, we expected to see a 20-50% difference in tumor size and mortality between Runx3 shRNA and control shRNA groups or Runx3-RV and GFP-RV groups; therefore, a sample size of 10-21 was chosen (t-test, α set at 0.05 or Log-rank test). Figure 1 sample sizes were chosen to achieve a sufficient cell number after sorting for subsequent processing, based on previous experiments within the lab.
Data exclusions
Describe any data exclusions. No data were excluded from analyses except in adoptive transfer/LCMV infection experiments, recipient mice that rejected transferred P14 cells (<~5%) were excluded (Figures 2-3 ).
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice were chosen at random for each group prior to all adoptive cell transfers and all tumor transplants.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For all mixed transfer experiments, blinding is not relevant. For tumor growth assessments, the investigator was aware of the cell type the was transferred into tumor-bearing mice.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
The PageRank analysis utilized in Figure 1 was described in detail previously (Yu et al., Nat. Immunol, 2017) .
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All unique materials used are readily available from the authors. b. Describe the method of cell line authentication used. B16-GP33 has been authenticated in our lab, as they form melanoma tumors and using P14 T cells in killing assays to confirm GP33 expression.. c. Report whether the cell lines were tested for mycoplasma contamination.
B16-GP33 cells were treated for mycoplasma contamination prior to use.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
All mice were of a C57BL6/J background and bred at UCSD and TSRI-FL or purchased from the Jackson Laboratory, including: WT or P14 mice with distinct expression of the congenic molecules CD45.1, CD45. The study did not involve human research participants.
Corresponding author(s): Goldrath, A.W.
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Data presentation
For all flow cytometry data, confirm that:
1. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2. The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
3. All plots are contour plots with outliers or pseudocolor plots.
4.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodological details 5. Describe the sample preparation. For isolation of CD8+ T cells from the small intestine intraepithelial lymphocyte (IEL) compartment, Peyer's patches were removed and the intestine was cut longitudinally and subsequently cut laterally into 0.5-1cm2 pieces that were then incubated with 0.154mg/mL dithioerythritol (DTE) in 10% HBSS/HEPES bicarbonate for 30min at 37°C while stirring. Kidneys, salivary glands and lungs were cut into pieces and digested for 30min with 100 U/mL type I collagenase (Worthington) in RPMI 1640, 5% FBS, 2mM MgCl2, 2mM CaCl2 at 37°C while shaking. Skin was processed similarly as described (ref 50) in which a 2cm2 area of the right flank was excised, pre-digested for 30min at 37°C and then enzymatically digested with 0.7 mg/mL collagenase D. After enzymatic incubations (skin, lungs, kidneys, salivary glands), tissues were further dissociated over a 70μm nylon cell strainer (Falcon). For isolation of lymphocytes, single-cell suspensions were then separated using a 44/67% Percoll density gradient. Spleens and lymph nodes were processed with the frosted ends of microscope slides. Red blood cells were lysed with ACK buffer (140 mM NH4Cl and 17 mM Tris-base, pH 7.4).
6. Identify the instrument used for data collection. For flow cytometry analysis, all events were acquired on a BD LSRFortessa X-20 or a BD LSRFortessa.
7. Describe the software used to collect and analyze the flow cytometry data.
The software used for collecting was BDFACS Diva software and for analyzing FlowJo software was used.
8. Describe the abundance of the relevant cell populations within post-sort fractions.
The purity of sorted samples were typically >98% pure. To check purity, an aliquot of sorted cells was analyzed or in cases where cells were sorted directly into Trizol, an additional aliquot of cells were sorted and purity was checked.
9. Describe the gating strategy used. For all analyses, gating schematics consisted of FSCxSSC gating of lymphocytes followed by singlet discrimination gates.
For Figure 1 , all sorted cells from the mLN, spleen or blood were sorted based on CD8a+ and congenic markers followed by CD127, KLRG1 or CD62l as indicated. For IEL or kidney populations CD8a IV negative CD8b+ cells were gated on and congenic markers were used for sorting.
For Figure 2 and 3, CD8a+ cells were gated on, then ametrine (shRNA experiments) or YFP (knockout experiments) then congenic markers (CD45.1, CD45.2, CD45.1.2, Thy1.1, Thy1.1.2 or Thy1.2) were gated on to distinguish mixed populations. Subsequent analysis of congenically distinct populations included expression levels of CD103, CD69, propidium iodide and Annexin V.
For Figure 3 , the same gating strategy was used as in Figure 2 except transduced cells were GFP+ instead of ametrine+. Gating and sorting strategy for Fig. 3 RNAseq data is discussed in Methods (p. 18).
For Figure 4 , analysis of mixed transfer populations in tumors was performed as described for Figure 2 . Transduced and expanded P14 cells were sorted on Ametrine or GFP reporter expression for efficacy experiments.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
